BioNTech Shares Face Dual Setback as Founders Depart and Earnings Miss

BioNTech shares crash after Q4 loss, disappointing 2026 forecast, and announcement that founders Sahin and Türeci will depart to start a new mRNA venture.

March 10, 2026, proved to be a punishing day for BioNTech investors. The biotech firm was hit with a one-two punch of significant news: the announcement that its founding duo would be stepping down and the simultaneous release of quarterly financial results that fell well short of expectations. The market's reaction was swift and severe, with the stock plummeting nearly 18 percent.

Financial Performance and Leadership Transition

The disappointing figures came from BioNTech's fourth quarter 2025 report. Revenue declined by 23.8 percent to €907.4 million, a direct result of sharply reduced global demand for COVID-19 vaccines. The company posted a loss per share of €1.25, a stark reversal from the €1.08 per share profit recorded in the same period a year earlier. For the full 2025 fiscal year, the net loss widened to €1.14 billion.

Compounding the negative earnings surprise was the concurrent revelation that founders Ugur Sahin and Özlem Türeci plan to depart by the end of 2026 to establish a new mRNA-focused venture. As part of this transition, BioNTech will contribute certain mRNA technologies and rights to the new entity. In return, it will receive a minority stake alongside potential milestone payments and royalties. A binding agreement is slated for signing before the close of the first half of 2026. The supervisory board has already initiated a search for successors.

Guidance Disappoints, Analysts React

Perhaps the heaviest blow to investor sentiment was the company's 2026 revenue forecast. Management projected sales between €2.0 and €2.3 billion, a figure that significantly undershot the average analyst estimate of €2.74 billion. The company attributed this anticipated shortfall primarily to declining COVID-19 vaccine revenue in its core European and U.S. markets. Concurrently, BioNTech plans to increase its adjusted research and development expenses to a range of €2.2 to €2.5 billion.

The nearly 18 percent single-day collapse erased approximately $4.26 billion in market capitalization. While shares managed a 7.7 percent rebound the following day, they remained far below their pre-announcement levels. The stock currently trades around €79.60, roughly 25 percent below its 52-week high of €105.90.

In response, several financial institutions revised their targets. Jefferies and Clear Street both lowered their price objectives to $138 and $167, respectively, but maintained their "Buy" recommendations. Analysts at Jefferies suggested that new leadership could ultimately benefit the company by improving communication and execution.

Oncology Pipeline Provides a Focal Point

Amid the turbulence, BioNTech emphasized that its clinical development pipeline remains unaffected by the executive changes. The company expects to have 15 ongoing Phase 3 trials in oncology active by year-end. Six late-stage study readouts are anticipated in 2026, including interim analyses for Pumitamig in triple-negative breast cancer and Gotistobart in lung cancer.

Particular attention is focused on T-Pam in endometrial cancer. Positive Phase 2 data here could potentially lead to the first oncology product launch in the company's history.

The year 2026 now stands as a pivotal period defined by two parallel timelines: the finalization of the founders' transition agreement by mid-year and the arrival of major clinical data that will test BioNTech's ongoing evolution from a vaccine specialist to a fully-fledged oncology company.